Gilead Sciences (NASDAQ:GILD)

unlike

Why Key Analyst Sees More Headwinds for Gilead Sciences

The recent performance from Gilead Sciences Inc. (NASDAQ: GILD) has analysts and investors concerned about the future. Currently the stock trades at less than eight times its forward earnings for 2016, ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Alphabet, Amazon, Dow Chemical, Ford, Gilead, Harley-Davidson, Western Digital and More

The stock market may have recently hit new highs, but stocks were indicated lower again on Friday. Earnings are being dominated by new-economy giants and held back by many of ...
Read Full Story »
biotech word cloud

Major Biotechs See Increased Short Interest Bets

The short interest data are out for the July 15 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
Female patient on gurney

Why Analysts Are Thinking M&A Is Back on the Table for Gilead

Gilead Sciences Inc. (NASDAQ: GILD) reported its second-quarter financial results after the markets closed on Monday. In the report we saw weakening trends in the hepatitis C vaccine (HCV) segment, ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Gilead, Sprint, Starbucks, Southwest Air, Texas Instruments, Disney, Nordstrom and More

Stocks hit a new high last week and are effectively looking for direction as very mixed earnings are coming with the start of a two-day Federal Open Market Committee (FOMC) ...
Read Full Story »
Prescription Drugs, Pills

Why Analysts Were Not Satisfied With Gilead Earnings

Gilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results after the markets closed on Monday. Although this is one of the world’s leading biotech companies, an earnings beat in this ...
Read Full Story »
Pills and tablets

What to Expect From Gilead Sciences Earnings

Gilead Sciences Inc. (NASDAQ: GILD) is scheduled to release its second-quarter financial results after the markets close on Monday. Within just the past month, the stock hit a 52-week low ...
Read Full Story »
Profit or Loss

10 Must-See Earnings for the Coming Week

24/7 Wall St. has put together a preview of some of the major companies reporting their quarterly results this week. We are in the heart of earnings season, in which ...
Read Full Story »
100 dollar bills

5 Companies Likely Buying Back the Most Stock in June and July

With stocks on the Dow Jones Industrial Average and the S&P 500 having just hit record highs, investors need at least a bit of an explanation here. After all, this ...
Read Full Story »
biotech word cloud

Short Sellers Become More Selective on Major Biotechs

The short interest data are out for the June 30 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. In ...
Read Full Story »
Pills and tablets

Biotechs With Drug Pipelines Closest to Zero Valuation

As biotech valuations and share price remain muted versus historic trends, investors have been evaluating which of the best biotech companies are offering the most upside. Other investors are looking ...
Read Full Story »
automatic inspection machine

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health ...
Read Full Story »
biotech word cloud

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After ...
Read Full Story »
Dollar Sign Island

20 Companies Buying Back the Most Stock in 2016

It is no secret that investors love dividends and stock buybacks. In recent years, there has been a larger shift into companies buying back shares of common stock, even while they ...
Read Full Story »
graph

Gilead Sciences Bounces on Preliminary Results

Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped ...
Read Full Story »